Growth in first half 2019 sales of Theraclion SA

+ 12%

Regulatory News:

THERACLION (Paris:ALTHE) (ISIN: FR0010120402; Mnemo: ALTHE, eligible PEA-SME), an innovative company specializing in the development of medical equipment for treatment by echotherapy including varicose veins, announced today its sales for the first semester of 2019, closing on June 30^th.

David Caumartin, Managing Director of Theraclion, says: "Based on its existing commercial platform, Theraclion is continuing its dynamic development of its Echopulse treatment solution on its historical pathologies, thyroid nodules and breast fibroadenoma. During the first half of this year, Theraclion sold four Echopulse units in Germany, allowing total sales close to one million euros, an increase of 12% compared to the first half of 2018. The CE mark obtained in April for the SONOVEIN varicose vein treatment solution, the adoption of our first trade agreement in May with a UK customer and the number of commercial treatments that have been performed since then confirm our ambition to enter a $ 10 billion¹ varicose veins market with our innovative treatment offer: no catheter, no injection of chemicals and no incision. Theraclion is expected to accelerate its sales growth in second half of 2019 to reach between 30% and 50% sales growth this year. This sales growth is expected to carry on the following years to achieve break even quarters within three years.”

Growth in sales of Theraclion SA: + 12%

Theraclion SA achieved a turnover of K€ 962 in the first six months of 2019.

Equipment sales, which account for 76% of the business, were up 11% compared to first semester 2018. In Germany, four treatment solutions were sold against only one in 2018 (H2). This dynamism is part of the broadening of the reimbursement in Germany of echotherapy for the treatment of thyroid nodules and breast fibroadenoma where the current number of insured is now reaching approximately 18.6 million people.

Following CE marking for the SONOVEIN varicose vein treatment solution in April 2019, the first commercial treatments started in May, generating 12 K€ in consumable sales as of June 30. Sold as a pay-per-use model, the SONOVEIN solution should, after a ramp-up period, generate close to € 200,000 per year per site, a source of high and recurring free cash flow.

Recurring revenue, consisting of the sale of consumables and services, increased by 46% in the first half of 2019, from 137 K€ to 200 K€.

Annual Sales / K€